KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Recursion Pharmaceuticals (RXRX) Other Gross PP&E Adjustments (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with $162.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 32.32% year-over-year to $162.9 million, compared with a TTM value of $162.9 million through Dec 2025, up 32.32%, and an annual FY2025 reading of $162.9 million, up 32.32% over the prior year.
  • Other Gross PP&E Adjustments was $162.9 million for Q4 2025 at Recursion Pharmaceuticals, up from -$47.8 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $162.9 million in Q4 2025 and bottomed at -$53.2 million in Q1 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $31.0 million, with a median of -$1.7 million recorded in 2021.
  • The sharpest move saw Other Gross PP&E Adjustments crashed 386.52% in 2021, then soared 4881.81% in 2022.
  • Year by year, Other Gross PP&E Adjustments stood at -$1.7 million in 2021, then skyrocketed by 4881.81% to $82.8 million in 2022, then grew by 11.85% to $92.6 million in 2023, then soared by 32.91% to $123.1 million in 2024, then soared by 32.32% to $162.9 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for RXRX at $162.9 million in Q4 2025, -$47.8 million in Q3 2025, and -$50.3 million in Q2 2025.